Background Intermittent preventive treatment (IPT) for malaria is used in infants, children, adults, and pregnant women. Dihydroartemisinin-piperaquine (DP) is an eff ective, well tolerated artemisinin-based combination therapy. The long half-life of piperaquine makes it attractive for IPT. We conducted a systematic review and meta-analysis to establish the effi cacy and safety of repeated treatment with DP.
Introduction
Malaria is a major, preventable cause of morbidity, mortality and adverse birth outcomes in sub-Saharan Africa. 1, 2 Although malaria mortality has fallen as a result of the scale-up of insecticide-treated bed nets and artemisinin-based combination therapies (ACTs), additional eff orts are needed. 3 Inter mittent preventive treatment (IPT) of malaria is a strategy for the control of malaria in pregnant women (IPTp), infants, children (seasonal malaria chemoprevention [SMC] ), 4 and potentially in high-risk subgroups of non-pregnant adults and schoolchildren. IPT involves the administration of curative doses of antimalarials at predefi ned intervals irrespective of malaria infection status.
Of the available ACTs, dihydroartemisininpiperaquine (DP) is one of the most attractive drugs for IPT. It is eff ective, with cure rates of 98% or more in non-pregnant and pregnant populations. [5] [6] [7] The long half-life of piperaquine (about 23 days [range [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] in adults and 14 days [range [10] [11] [12] [13] [14] [15] [16] [17] [18] in children) 6 provides 1-2 weeks' longer post-treatment prophylaxis than artemether-lumefantrine (AL, half-life 3-6 days), 8 artesunate-amodiaquine (half-life 6-18 days), 9 or sulfadoxine-pyrimethamine (SP, half-life 4-11 days), 10 and a similar duration of post-treatment prophylaxis as mefl oquine (half-life 10·5-14 days). 11 It is well tolerated compared with other antimalarials: side-eff ects are typically limited to minor gastrointestinal adverse events, mild headache, and dizziness. 12 DP can cause dose-dependent prolongation of the QT interval 13 and is not recommended in patients with congenital long QT syndrome (about one in 2500 children) 14 or who are taking other QT prolonging drugs. 13 Numerous drugs have been associated with QT prolongation, including multiple classes of antibiotics (eg, erythromycin, 15 quinolones, 15 co-trimoxazole 16 ) and antimalarials. 17 Mild QT prolongation is clinically silent, but extreme prolongation can cause arrhythmias, including torsade de pointes, a potentially fatal polymorphic ventricular tachycardia occurring in roughly one of 10 000 exposures to QT prolonging drugs. 18 Diagnosis of prolonged QT requires electrocardiograms (ECG); the normal range diff ers for men and women, as well as children and adults. Few studies of DP have assessed ECGs. 19, 20 Administration of DP with food, particularly fat, increases the bioavailability, leading to increased drug concentrations and a greater degree of QT prolongation, which persists for a longer duration. 21 Additionally, piperaquine concentrations might also be increased when co-administered with drugs that are CYP3A4-inhibitors (eg, some protease inhibitors). 13 For these reasons, the drug manufacturer recommends obtaining ECGs to monitor therapy when clinically indicated. However, this is not practical if DP is to be given as IPT in resource poor settings and studies assessing the cardiotoxicity of DP when provided for case management show the risk to be low. 22 Furthermore, neither DP nor AL displayed an in-vitro signal for a signifi cant pro-arrhythmic risk or appear to induce potential torsadogenic eff ects. 23 However, piperaquine is elimin ated slowly and theoretically this risk might be increased when repeated doses are given, especially when given monthly. We conducted a systematic review and meta-analysis to assess the effi cacy, safety, and tolerability of repeated dosing of DP when used for case management, IPT, mass drug administration or seasonal malaria chemoprevention.
Methods

Search strategy
We did a systematic literature search according to PRISMA guidelines 24 on Sept 1, 2016, using simple search terms "human" AND "dihydroartemisinin-piperaquine" OR "DHA-PPQ" (see appendix). Studies were eligible if they were randomised controlled trials (RCTs) or prospective cohort studies involving repeat exposures to standard 3-day courses of DP for either chemoprevention (IPT/SMC), mass drug administration, or treatment of clinical malaria, conducted at any time and in any geographic location. The search was restricted to the English language (appendix).
Data management
Two independent reviewers (SK, JG) screened titles, abstracts, and full texts and agreed on fi nal study eligibility. Reviewers independently extracted data using a standardised form and database. If required, additional information was obtained from authors.
Quality assessment
The Cochrane Collaboration's tool was used to assess the quality and risk of bias of clinical trials. 25 The quality of observational studies was assessed using the Newcastle Ottawa Scale.
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Research in context
Evidence before this study Malaria is a major, preventable cause of morbidity, mortality, and adverse birth outcomes in sub-Saharan Africa. Intermittent preventive treatment (IPT) of malaria, which involves curative doses of antimalarials at predefi ned intervals irrespective of malaria infection status, is a strategy for the control of malaria in pregnant women, infants, and children (seasonal malaria chemoprevention [SMC]). Dihydroartemisinin-piperaquine (DP) is an eff ective, well tolerated antimalarial, and the long half-life of piperaquine makes DP an attractive choice for IPT. However, DP is known to cause dose-dependent prolongation of the QT interval, and limited data exists on whether the risk of QT prolongation is increased with repeated dosing. We conducted a systematic review and meta-analysis to establish the effi cacy and safety of repeated treatment with 3-day courses of DP.
We searched Medline, Embase, Web of Science, Scopus, CINAHL Plus, the Cochrane Library databases, WHO Global Health Library, the Malaria in Pregnancy Consortium (MiPc) Library, 'grey literature' databases (unpublished literature including ongoing clinical trials, ongoing PhDs, unpublished PhDs, aborted research, and any other unconventional unpublished literature on the topic), and conference abstracts for articles published before Sept 1, 2016 using the terms: "human" AND "dihydroartemisinin-piperaquine" OR "DHA-PPQ", and restricting the language to English. There are several reviews on the safety and effi cacy of a single course of DP for treatment (ie, case management), and one review of studies of IPT in children (now called SMC) (including two using DP or other piperaquine combinations) and one of IPT in schoolchildren (including one trial using DP).
Added value of this study
To our knowledge, this is the fi rst review and meta-analysis to specifi cally assess the safety and effi cacy with repeated courses of DP for case management, IPT, mass drug administration or seasonal malaria chemoprevention in all age groups when compared with placebo or other antimalarial interventions. Monthly DP was more eff ective than most other options for the prevention of malaria, and appeared to be well tolerated and safe, with less serious adverse events than many comparator interventions and no evidence for increased risk of adverse cardiac events. Nevertheless, data on cardiotoxicity is still scarce.
Implications of all the available evidence DP is a valuable potential candidate for use as IPT and could greatly reduce malaria morbidity and mortality. Additional studies incorporating electrocardiogram measurements are needed to confi rm the cardiac safety of repeated monthly dosing.
See Online for appendix
Data analysis
Random-eff ects meta-analysis was used to generate pooled incidence rate ratios (IRR) and relative risks, or risk diff erences when there were zero events in both study groups, to compare the eff ect of DP relative with other antimalarials or placebo on malaria incidence and tolerability; odds ratio (OR) was used for serious adverse events (SAEs) because they are rare events. To correct for studies reporting no SAEs in either the DP or comparison group, a fi xed eff ects model with continuity correction of 0·5 was used to generate Mantel-Haenzel pooled ORs for each study to be informative. 26 Heterogeneity was expressed as I² value and categorised as low if I² was 0-40%, moderate if I² was 30-60%, substantial if I² was 50-90%, and considerable if I² was 75-100%. 24 Analyses were stratifi ed by study type (case management vs IPT/SMC/mass drug administration) and geographic location (east Africa, west Africa, and Asia). Due to scarcity of data, we could not stratify on pregnancy status. The infl uence of study quality on results was assessed by sensitivity analyses. Publication bias was assessed through funnel plots. Two-tailed p-values <0·05 were considered statistically signifi cant.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Our search identifi ed 898 citations; after title review, 380 abstracts and 46 full text articles (29 distinct studies) were reviewed (fi gure 1). 11 studies were eligible: one cohort study in pregnant women (n=5288), 30 one RCT of repeated treatments in children younger than 5 years (n=312), 20 and nine RCTs with IPT/SMC (henceforth referred to as IPT). Of the nine RCTs, fi ve were in children younger than 5 years (n=5481), 6 ,31-34 one in schoolchildren (n=740), 35 one in adult men at occupational risk of malaria (n=961), 36 and two in pregnant women (n=1846; 37,38 table). In total, there were 14 628 participants; 4883 in DP groups, of whom 4511 were exposed to DP and 3935 received at least two courses of DP, including 762 pregnant women and 1913 children aged less than 5 years. The remaining 9745 were exposed to placebo or other comparator therapy (including 990 exposed to SP-piperaquine). The 4511 participants exposed to DP received a total of 18 873 courses, with 18 297 courses taken by the 3935 participants who received at least two doses, some of whom received as many as 18 monthly doses. Several diff erent dosing intervals were studied, including monthly (including in pregnancy), every 2 months, quarterly, and three times during the second and third trimester of pregnancy. Comparator interventions included placebo, AL, SP, SP+amodiaquine, SP + piperaquine, SP + chloroquine, and piper aquine + cotrimoxazole. All studies were conducted in areas with no or low parasite resistance to piperaquine or the artemisinins.
The Cochrane Collaboration tool scored four RCTs as low risk of bias and six as moderate risk of bias (appendix). The Newcastle Ottawa Scale suggested a moderate risk of bias for the single cohort study.
Protective effi cacy
Repeated fi rst-line course of DP for case management was associated with a 16% lower risk of parasitological treatment failure by day 28 compared with AL, but only one trial provided data for analysis (IRR 0·84 95% CI 0·81-0·86). 20 Monthly DP for IPT was associated with an 84% reduction in the incidence of malaria parasitaemia measured by microscopy compared with placebo 29 reporting on the use of DP for rescue treatment among pregnant women included nine women who received at least two courses of DP (six received three courses and three received two courses), but all women had also received a preceding course of either quinine or intravenous artesunate with or without clindamycin, and there were no control women who had not received DP. *One trial 28 comparing seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine plus amodiaquine vs placebo SMC (passive case detection and case management with either DP or AL during the malaria transmissions season) was excluded because only 27 of 800 children (3·4%) in placebo SMC group (ie, the DP case management group) received two or more courses of DP and safety data by number of courses received were not available. (pooled IRR; fi gure 2). This was 75% in east Africa, 91% in west Africa, and 97% in adults in Thailand 36 (appendix). Monthly IPT with DP provided similar effi cacy to monthly SP+amodiaquine for preventing any parasitaemia, but inferior effi cacy compared with monthly SP+primaquine (fi gure 3). Monthly IPT-DP was signifi cantly better than daily co-trimoxazole, or monthly IPT-SP for the prevention of malaria infection.
Dosing of IPT-DP on a less than monthly schedule (every 2 months 36 or 3 months 35 ) provided signifi cantly less protection against any parasitaemia than monthly dosing (fi gure 3).
The considerable heterogeneity (I²>75%) among placebo controlled RCTs was partly explained by diff erence in quality of the trials as established by the Cochrane Collaboration's tool: 25 there was no heterogeneity in the two RCTs classifi ed as having low potential LAMP=loop-mediated isothermal amplifi cation. *Numbers in brackets represent the number who received one or more and two or more courses of DP, if reported to be diff erent from the overall sample size in the DP group. †In addition to any other SAEs reported by the study, all hospital admissions and deaths were considered SAEs. SAEs were reported unrelated to study drugs unless otherwise noted: Bigira and colleagues reported 19 (4·5%) grade 3-4 AEs as possibly related to study drugs, with no signifi cant diff erences between the intervention groups. Desai and colleagues reported one drug related SAE (an allergic reaction to DP); Kakuru and colleagues reported one patient who developed anaemia after both the fi rst and second dose of DP, after which DP was stopped; Kamya and colleagues reported eight (5·6%) AEs possibly related to study drugs, with no signifi cant diff erences between the intervention groups; Lwin and colleagues reported that four patients withdrew due to drug related AEs (two in the DP every other month group and two in placebo group). ‡DOT by study staff , fi rst dose=only the fi rst dose of each course was administered as DOT. §The total number of doses was divided by three to estimate the number of courses and rounded to the nearest whole number. ¶Reported prevalence over the course of pregnancy (incidence was not reported). ||Average duration between courses 4·2 months **Average duration between courses 2·2 months † †Intention to treat included 750 in the DP group and 740 in the SP+AQ group, but due to allocation errors, 757 were given DP and 742 were given SP+AQ.
Table:
Details of included studies for bias (I²=0%) but high heterogeneity (I²=99·6%) among the four RCTs classifi ed as having moderate potential for bias (appendix). Absence of variability in study quality within each comparator drug subgroup precluded further assessment of the infl uence of the risk of bias on the heterogeneity by comparator drug.
Figure 2:
Pooled incidence rate ratio for any parasitaemia, monthly dihydroartemisinin-piperaquine vs placebo DP=dihydroartemisinin-piperaquine. PYAR=person-years at risk. IR=incidence rate. IRR=incidence rate ratio. Lwin and colleagues 36 and Zongo and colleagues 6 did not report PYAR, instead they reported cumulative incidence over a year. PYAR was calculated based on the incidence rate and number of events. Zongo and colleagues' 6 numbers are based on intent to treat.
Weight (%) IRR for any parasitaemia (95% CI) Country
Bigira, 2014 31 Bojang, 2010 32 Kamya, 2014 34 Lwin, 2012 36 Nankabirwa, 2014 35 Zongo, 2015 6
Overall (I²=99·4%, p=0·000) 36 and Zongo and colleagues 6 did not report PYAR. PYAR was calculated based on the incidence rate and number of events. Cisse and colleagues 32 reported cumulative incidence. Kakuru 37 reported detection of malaria parasites by LAMP at each visit as the prevalence of positive tests during pregnancy out of all tests. Zongo and colleagues' 6 numbers are based on intention to treat.
Weight (%) IRR for any parasitaemia (95% CI)
Country
Monthly DP vs CTX for IPT Bigira, 2014 31 Kamya, 2014 34 
Subtotal (I²=30·7%, p=0·230)
Monthly DP vs SP for IPT Bigira, 2014 31 Kamya, 2014 34 Desai, 2015 37 Kakuru, 2015 38 Subtotal (I²=97·2%, p=0·00)
Monthly DP vs SP+PQ for IPT
Bojang, 2010 32 Cisse, 2009 33 
Subtotal (I²=0·0%, p=0·854)
Monthly DP vs SP+AQ for IPT Bojang, 2010 32 Cisse, 2009 33 Zongo, 2015 6 Subtotal (I²=81·5%, p=0·004) Geographic stratifi cation did not explain the heterogeneity (appendix).
Monthly DP vs
Among 3960 participants, after excluding arms of studies where most had received no or only 1 course of DP, 30, 37 133 SAEs were reported, including 23 in patients receiving DP+co-trimoxazole. Including all 4883 participants in DP groups (3935 of whom received at least two courses), 233
SAEs were reported. An additional four SAEs were reported in 990 reci pients of SP+piperaquine. Among 3180 participants receiving other treatments and 5575 receiving placebo, 287 and 186 SAEs were reported, respectively (table 1) .
After correction for zero events, repeated DP exposure was associated with a signifi cantly lower odds of SAEs 30 : only 64 of 408 DP recipients received two or more courses of DP, but information of SAEs by number of courses received was not available.
Weight (%) OR (95% CI) Country
Comparator therapy
Comparator: SAE/exposed DP: SAE/exposed Monthly DP vs CTX for IPT Bigira, 2014 31 Kamya, 2014 34 Subtotal (I²=0·0%, p=0·560)
Monthy DP vs Placebo for IPT
Bigira, 2014 31 Bojang, 2010 32 Kamya, 2014 34 Lwin, 2012 36 Nankabirwa, 2014 38 Zongo, 2015 6 Subtotal (I²=48·9%, p=0·081)
Monthly DP vs SP for IPT
Bigira, 2014 31 Kamya, 2014 34 Desai, 2015 37 Kakuru, 2015 38 Subtotal (I²=63·4%, p=0·042)
Monthly DP vs SP+PQ for IPT
Bojang, 2010 32 Cisse, 2009 33 Subtotal (I²=0·0%, p=0·382)
Monthly DP vs SP+AQ for IPT
Bojang, 2010 32 Cisse, 2009 33 Zongo, 2015 xx Subtotal (I²=0·0%, p=0·841)
Monthly DP vs Alternative IPT-DP or IST-DP Lwin, 2012 36 Nankabirwa, 2014 35 Desai, 2015 37 Kakuru, 2015 38 Subtotal (I²=29·3%, p=0·236)
DP vs Other therapies for case management
Poespoprodjo, 2014 30 Poespoprodjo, 2014 30 Subtotal (I²=0·0%, p=0·562)
DP vs AL for case management
Wanzira, 2014 20 Wanzira compared with placebo, co-trimoxazole, or IPT-SP (fi gure 4). IPT-DP was also associated with fewer hospital admissions than IPT-SP (appendix). Repeated case management with DP was associated with fewer hospital admissions compared with AL (appendix). None of the 11 studies reported SAEs was consistent with sudden cardiac death. Overall, 15 deaths were reported among those exposed to DP, two among those exposed to SP+piperaquine, 18 among those exposed to other comparator therapies, and four among those in placebo groups. No studies reported any sudden or unexplained deaths (fi gure 5, appendix). IPTp-DP was not associated with an increased risk of loss to follow-up (which could refl ect undetected or unreported sudden Subtotal (I2= 0·0%, p=0·647)
Monthy DP vs placebo for IPT Bigira, 2014 31 Bojang, 2010 32 Kamya, 2014 34 Lwin, 2012 36 Zongo, 2015 6 Nankabirwa, 2014 35 Subtotal (I2=0·0%, p=0·847)
Monthly DP vs SP for IPT
Bigira, 2014 31 Kamya, 2014 34 Desai, 2015 37 Kakuru, 2015 38 Subtotal (I2=0·0%, p=0·652)
Monthly DP vs SP+PQ for IPT
Bojang, 2010 32 Cisse, 2009 33 Subtotal (I2=0·0%, p=0·597)
Monthly DP vs SP+AQ for IPT
Bojang, 2010 32 Cisse, 2009 33 Zongo, 2015 6 Subtotal (I2=0·0%, p=0·814)
Monthly DP vs alternative IPT-DP or IST-DP Lwin, 2012 36 Nankabirwa, 2014 35 Desai, 2015 37 Kakuru, 2015 38 Subtotal (I2=0·0%, p=0·553) DP vs other therapies for case management death) compared with co-trimoxazole, SP, SP + piperaquine, or SP+amodiaquine, but was associated with a 47% higher risk of loss to follow-up compared with placebo (appendix).
The eff ect of DP on cardiac repolarisation was assessed in 19 HIV-unexposed 31 and seven HIV-exposed children (Dorsey, unpublished) and 30 pregnant women. 38 In the 26 children, 183 ECGs were conducted at baseline and follow-up (4-6 h after the third dose of DP with each monthly course); all of the baseline and follow-up ECGs had a QTc less than 450 ms with a mean QTc of 396 ms (SD 31·3, range 278-444). There were no diff erences in the mean QTc intervals measured after the third dose for children who had been prescribed three to fi ve previous courses of DP (mean QTc 405 ms, SD 26), six to ten previous courses of DP (388 ms, 33), or 11-18 previous courses of DP (396 ms, 33) . None of the 30 pregnant women who underwent ECG measurements at 28 weeks' gestational age pre-dosing and post-dosing had QTc intervals greater than 450 ms. 38 The median increase in QTc from baseline to 4-6 hours after the third dose was 30 ms (range -30 to 50) and 20 ms (-10 to 50) in women randomised to receive monthly DP (n=13) and 3 doses of DP (n=17), respectively, compared with 5 ms (-40 to 60) in women who received three doses of SP (n=12, p=0·57 and 0·28 for monthly and three dose DP compared with three dose SP).
IPT-DP was associated with similar cumulative risk of any vomiting compared with placebo, SP, and SP+amodiaquine, and with a lower risk compared with SP+primaquine (appendix). In the single treatment study with tolerability data, DP was associated with a lower risk of vomiting compared with AL (RR 0·52, 95% CI 0·45-0·61). 20 In children under 5 years of age, both IPT-DP and IPT-SP were associated with more vomiting during the fi rst course than subsequent monthly courses (DP around 4% vs <2%; SP around 3·5% vs <2%). 6 No vomiting was reported among school-aged (6-14 years) children receiving monthly IPT-DP after any of the three courses. 35 Treatment of clinical malaria with DP was not associated with more vomiting than AL for the fi rst and second courses, and for the third course, participants given DP vomited less than those given AL (2·8% vs 7·8% p=0·08). 20 IPT-DP was not associated with an increased risk of diarrhoea compared with placebo, SP+amodiaquine, SP+primaquine, or IPT-SP in six studies (appendix).
Only four studies provided data on rash or allergic reactions, and no study reported any SAEs due to allergic reactions. IPT-DP was not associated with an increased risk of rash compared with placebo, SP+primaquine or SP+amodiaquine (appendix).
Discussion
This meta-analysis suggests that DP is as safe as other combinations assessed for IPT or the repeat treatment of clinical malaria, and that it was well tolerated. DP provided superior protection against malaria and resulted in fewer hospital admissions than comparators. In comparison with dosing every 2 or 3 months, monthly administration of DP provided much better protection from malaria, without increasing the risk of adverse events or adversely aff ecting tolerability. [35] [36] [37] [38] DP, like some other antimalarials, has been associated with dose dependent risk for QTc prolongation. A previous review assessing the risk of QTc prolongation following a single course of treatment found no diff erence in the risk for prolonged QTc between DP and AL, but DP was associated with more frequent prolongation of the QTc interval compared with mefl oquineartesunate. 39 No cardiac arrhythmias or sudden death were reported for any of the drugs, although it is possible that sudden death due to a cardiac arrhythmia could have been incorrectly attributed to other causes. Similarly, in our meta-analysis, no cardiac events were reported among 3935 recipients of repeat courses of DP involving 18 297 courses of DP ranging from two to 18 courses per individual. As only three studies in diff erent populations assessed the eff ect of DP on the ECG, it was not possible to do a meta-analysis to assess the risk of repeated courses of DP on the ECG; however, no signifi cant QT prolongation was reported with repeat dosing in the individual studies. Furthermore, the risk of death was not signifi cantly increased following receipt of repeat courses of DP, suggesting no signifi cant increased risk of sudden cardiac death, although the rare nature of this event makes it diffi cult to rule out. It should be noted, however, that although DP was not associated with increased loss to follow-up compared with comparators, there was more loss to follow-up among participants in the DP group in the studies comparing DP against placebo. This was driven primarily by the high loss to follow-up in Lwin and colleagues, 36 which was unrelated to the intervention since only four withdrew due to adverse events: two from the IPT group and two from the placebo group. The rest were lost due to other reasons.
The clinical relevance of the dose dependent risk for QTc prolongation with DP is not clear, since the proarrhythmic potential of piperaquine in vitro appears lower than chloroquine and similar to AL. 23 One post-marketing study, comparing a compressed 2-day regimen of DP with placebo, has reported clinically signifi cant QT prolongation among participants exposed to DP. 19 Given the potential for dose accumulation with monthly dosing, 36 it was reassuring to fi nd that the studies in children did not fi nd evidence that repeat monthly courses were associated with greater degrees of QT prolongation than the fi rst course, even among children that had received ten or more monthly courses 31 (Dorsey, unpublished data).
It is possible that the absence of additional QTc prolongation with repeat courses refl ects the fi nding that QTc interval returns to normal within approximately 12-48 h following the last dose after each course.
Nevertheless, some increase in QTc prolongation with increasing number of courses could not be excluded in pregnant women, 38 and the strength of the evidence to date is limited because ECGs were only done in three studies involving 56 participants receiving monthly courses, thus more studies are needed. Advances in mobile adapted technology, such as Smartheart or AliveCor, might allow for improved monitoring of patients in remote and resource poor settings in the future.
Our search did not fi nd any studies where repeat courses of DP were provided as part of malaria elimination campaigns that often involve multiple rounds of mass drug administration within a single year. However, our fi ndings with DP as IPT are likely to be generalisable to mass drug administration since both strategies involve asymptomatic carriers of malaria parasites and individuals without malaria parasites at the time of drug administration.
The few people exposed to multiple courses of DP to date precludes our ability to detect an increased risk of an arrhythmia such as torsadogenic event that occur in about one in 10 000 exposures to QT prolonging drugs; our overall sample size can only exclude (95% CI) such events in one in 6099 exposures. The fact that diff erent patient populations were grouped is a potential weakness, as the QTc (and risk for cardiotoxicity) is aff ected by age, sex, and pregnancy status, and achieved drug concentrations might also vary by patient population and gestational age; however, the paucity of data precluded reviewing the groups individually. The included studies involving young children were conducted before WHO's dose increase for DP in children aged 1-4 years, 4 and continued collection of safety data with the new dose is needed. One of the treatment studies included many participants who only received a single course of DP. However, no details were provided in the source study that allowed a breakdown of SAEs by number of courses. Finally, it is possible that restricting to English language excluded relevant studies published in other languages.
In this meta-analysis of nearly 4000 patients exposed to repeated courses of DP, IPT-DP was highly eff ective for the prevention of malaria and reduced all-cause hospital admission compared with other drugs, particularly when provided as monthly courses. Overall, DP was well tolerated, with no evidence of increased frequency of mild or serious adverse events with repeated dosing. The data do not suggest that the known risk of QT prolongation increases with repeated monthly courses, or an increased risk of cardiac events or death following repeated dosing. DP is a valuable potential candidate for use as IPT and ongoing monitoring for cardiac events is needed to provide further reassurance of its safety with repeat doses.
